Blincyto

Blincyto

blinatumomab

Manufacturer:

Amgen

Distributor:

Zuellig Pharma

Marketer:

Amgen
Concise Prescribing Info
Contents
Blinatumomab
Indications/Uses
CD19 +ve B-cell precursor acute lymphoblastic leukemia (ALL) in 1st or 2nd complete remission w/ minimal residual disease (MRD) ≥0.1% in adults & childn. Relapsed or refractory CD19 +ve B-cell precursor ALL in adults & childn.
Dosage/Direction for Use
MRD +ve B-cell precursor ALL 1 cycle for induction followed by up to 3 additional cycles for consolidation. Single induction or consolidation cycle: 28 days of continuous IV infusion followed by 14 days treatment-free interval (total of 42 days). Patient weighing ≥45 kg Induction cycle 1 & consolidation cycles 2-4 (fixed-dose): 28 mcg daily on days 1-28; 14-day treatment-free interval on days 29-42. Patient weighing <45 kg Induction cycle 1 & consolidation cycles 2-4 (BSA-based dose): 15 mcg/m2 daily (Max: 28 mcg daily) on days 1-28; 14-day treatment-free interval on days 29-42. Premed: Adult Prednisone 100 mg IV or equiv (eg, dexamethasone 16 mg) 1 hr prior to 1st dose in each cycle. Ped Dexamethasone 5 mg/m2 (Max dose: 20 mg) prior to 1st dose in 1st cycle & when restarting infusion after ≥4 hr interruption in 1st cycle. Relapsed or refractory B-cell precursor ALL 2 induction cycles followed by 3 additional cycles for consolidation & up to 4 additional cycles of continued therapy. Single induction or consolidation cycle: 28 days continuous IV infusion followed by 14 days treatment-free interval (total of 42 days). Single cycle of continued therapy: 28 days of continuous IV infusion followed by 56 days treatment-free interval (total of 84 days). Patient weighing ≥45 kg Induction cycle 1 (fixed-dose): 9 mcg daily on days 1-7; 28 mcg daily on days 8-28; 14-day treatment-free interval on days 29-42. Induction cycle 2 & consolidation cycles 3-5 (fixed dose): 28 mcg daily on days 1-28; 14-day treatment-free interval on days 29-42. Continued therapy cycles 6-9 (fixed dose): 28 mcg daily on days 1-28; 56-day treatment free interval on days 29-84. Patient weighing <45 kg Induction cycle 1 (BSA-based dose): 5 mcg/m2 daily (Max: 9 mcg daily) on days 1-7; 15 mcg/m2 daily (Max: 28 mcg daily) on days 8-28; 14-day treatment-free interval on days 29-42. Induction cycle 2 & consolidation cycles 3-5 (BSA-based dose): 15 mcg/m2 daily (Max: 28 mcg daily) on days 1-28; 14-day treatment-free interval on days 29-42. Continued therapy cycles 6-9 (BSA-based dose): 15 mcg/m2 daily (Max: 28 mcg daily) on days 1-28; 56-day treatment-free interval on days 29-84. Premed: Adult Dexamethasone 20 mg 1 hr prior to 1st dose of each cycle, prior to a step dose (eg, cycle 1 day 8) & when restarting an infusion after an interruption of ≥4 hr. Ped Dexamethasone 5 mg/m2 (Max dose: 20 mg) prior to 1st dose in the 1st cycle, prior to step dose (eg, cycle 1 day 8), & when restarting an infusion after an interruption of ≥4 hr in the 1st cycle.
Contraindications
Special Precautions
Discontinue permanently in life-threatening cytokine release syndrome (CRS). Interrupt or discontinue use if neurological toxicities or tumor lysis syndrome (TLS) occurs. Interrupt treatment if prolonged neutropenia occurs; if transaminases >5x ULN or bilirubin >3x ULN. Leukoencephalopathy, especially in patients w/ prior treatment w/ cranial irradiation & antileukemic chemotherapy including systemic high-dose MTX or intrathecal cytarabine. Monitor for signs & symptoms of CRS, neurological toxicities, infections, TLS, pancreatitis; lab parameters (eg, WBC & ANC) during infusion; ALT, AST, γ-glutamyl transferase & total blood bilirubin prior to start of & during treatment. Administer corticosteroids for severe or life-threatening CRS; antibiotics for serious infections; pretreatment nontoxic cytoreduction & on treatment hydration during treatment for prevention of TLS. Not recommended w/ concomitant vaccination w/ live virus for at least 2 wk prior to start of & during treatment, & until immune recovery following last cycle. Refrain from driving & engaging in hazardous occupations or activities eg, operating heavy or potentially dangerous machinery. Females of reproductive potential should use contraception during treatment & at least 48 hr after the last dose. Pregnancy. Do not breastfeed during & for at least 48 hr after treatment. Ped patients. Elderly.
Adverse Reactions
Neutropenia, leukopenia, thrombocytopenia, anemia; arrhythmia; pyrexia, chills, edema; CRS; unspecified pathogen infections, bacterial/viral/fungal infectious disorders; infusion-related reaction; decreased Ig, increased wt, hypertransaminasemia; back pain; headache, tremor, aphasia, dizziness, encephalopathy; insomnia; cough; rash; hypotension. Fatal pancreatitis.
Drug Interactions
Risk w/ CYP450 substrates, particularly those w/ narrow therapeutic index.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01FX07 - blinatumomab ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.
Presentation/Packing
Form
Blincyto powd for soln for infusion 35 mcg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in